Tina Badinski

Ms. Tina Badinski

University hospital Zurich, Zürich, Switzerland
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 November 2024 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
Tina BadinskiTina Badinski
Tina Badinski
SSSalome N. Seiffert
Salome N. Seiffert
FGFabian Grässli
Fabian Grässli
BFBaharak Babouee Flury
Baharak Babouee Flury
UBUlrike Besold
Ulrike Besold
OGon behalf of the SURPRISE Study Group
on behalf of the SURPRISE Study Group
The objective of this study was to determine the prevalence, molecular epidemiology, and risk factors for gut colonization with extended-spectrum β-lactamase-producing Enterobacterales (ESBL-E), carbapenemase-producing Enterobacterales (CPE), and vancomycin-resistant enterococci (VRE) in healthcare workers (HCWs). In September/October 2022, we performed a cross-sectional study among HCW from 14 institutions in Northeastern Switzerland. HCWs reported risk factors for antimicrobial resistance (covering the last 12–24 months) and provided rectal swabs. Swabs were screened for ESBL-E, CPE, and VRE; whole-genome sequencing (WGS) was performed to assess the genetic relatedness. Logistic regression was used to identify occupational and non-occupational risk factors. Among approximately 22,500 employees, 1,209 participated (median age 46 years, 82% female). Prevalences of ESBL-E ( n = 65) and CPE ( n = 1) were 5.4% [95% confidence interval (CI) 4.2–6.8] and 0.1% (95% CI 0.0–0.5), respectively; no VREs were detected. In the multivariable analysis, non-European ethnicity [adjusted odds ratio (aOR) 7.0, 95% CI 1.4–27.3], travel to high-risk countries (aOR 4.9, 95% CI 2.5–9.3), systemic antibiotics (aOR 2.1, 95% CI 1.1–3.7), antibiotic eye drops (aOR 4.7, 95% CI 1.7–11.9), and monthly sushi consumption (aOR 2.4, 95% CI 1.4–4.3) were positively associated with ESBL-E colonization, whereas alcohol consumption (aOR 0.5 per glass/week, 95% CI 0.3–0.9) was negatively associated with ESBL-E colonization. Occupational factors showed no association. Among ESBL- Escherichia coli , ST131 (15 of 61, 25%) and bla CTX-M-15 (37/61; 61%) were most common; one isolate co-harbored bla OXA-244 . WGS data did not show relevant clustering. Occupational exposure is not associated with ESBL-E colonization in HCW. Given the potential public health and antibiotic stewardship implications, the role of sushi consumption and antibiotic eye drops as risk factors should be further elucidated.

7 May 2022 in Infectious Diseases Now
Verified
Journal Article
Open access
EKE. Kampouri
E. Kampouri
PFP. Filippidis
P. Filippidis
MWM. Wölfle
M. Wölfle
ATA. Taveira
A. Taveira
Tina BadinskiTina Badinski
Tina Badinski
BGBenoit Guery
Benoit Guery
Clostridioides difficile infection (CDI) is a disease with high morbidity and mortality rates. The objective of this study was to describe CDI epidemiology and patient characteristics over a 5-year period in Switzerland and assess risk factors for mortality, recurrence and severe CDI. We retrospectively included all consecutive CDI cases having occurred in adult patients hospitalized in two tertiary centers: the Lausanne University Hospital (1000 beds) and the University Hospital of Zurich (900 beds), between 2014 and 2018. Suspected cases of CDI were identified from the microbiology laboratory database on the basis of a positive test and confirmed by records review. During first CDI episodes, the median age was 67 years and the median Charlson comorbidity index (CCI) score was 5. All in all, 299 out of 826 patients (36.2%) had severe infection based on the Infectious Diseases Society of America criteria. In the multivariable analysis, CCI was associated with increased risk of mortality. None of the factors recorded on admission were significantly associated with increased risk of recurrence. In the multivariable analysis, male sex and CCI were associated with severity, while immunosuppression was associated with less severe presentation. If we did not identify any criteria on admission that could be predictive of recurrences, this could be explained the retrospective nature of the study. A higher comorbidity index is a key driver for severe CDI and mortality. Reporting of CDI is not mandatory in Switzerland; structuration of CDI reporting should be a short-term priority.

Verified
Journal Article
Open access
PDF file
PFParaskevas Filippidis
Paraskevas Filippidis
EKEleftheria Kampouri
Eleftheria Kampouri
MWMaximilian Woelfle
Maximilian Woelfle
Tina BadinskiTina Badinski
Tina Badinski
ACAntony Croxatto
Antony Croxatto
BGBenoit Guery
Benoit Guery
Objectives: Clostridioides difficile infection (CDI) is the leading cause of healthcare-associated diarrhea, often complicated by severe infection and recurrence with increased morbidity and mortality. Data from large cohorts in Switzerland are scarce. We aimed to describe diagnostic assays, treatment, outcomes, and risk factors for CDI in a large cohort of patients in Switzerland. Methods: We conducted a retrospective cohort study of CDI episodes diagnosed in patients from two tertiary care hospitals in Switzerland. During a 3-month follow-up, we used a composite outcome combining clinical cure at day 10, recurrence at week 8, or death, to evaluate a patient’s response. Unfavorable outcomes consisted in the occurrence of any of these events. Results: From January 2014 to December 2018, we included 826 hospitalized patients with documented CDI. Overall, 299 patients (36.2%) had a severe infection. Metronidazole was used in 566 patients (83.7%), compared to 82 patients (12.1%) treated with vancomycin and 28 patients (4.1%) treated with fidaxomicin. Overall mortality at week 8 was at 15.3% (112/733). Eighty-six patients (12.7%) presented with clinical failure at day 10, and 78 (14.9%) presented with recurrence within 8 weeks; 269 (39.8%) met the composite outcome of death, clinical failure, or recurrence. The Charlson Comorbidity Index score (p < 0.001), leukocytes > 15 G/L (p = 0.008), and the use of metronidazole (p = 0.012) or vancomycin (p = 0.049) were factors associated with the composite outcome. Conclusions: Our study provides valuable insights on CDI treatment and outcomes in Switzerland, highlights the heterogeneity in practices among centers, and underlines the need for the active monitoring of clinical practices and their impact on clinical outcomes through large multicentric cohorts.